GREENWICH, CT
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)THE FIBROLAMELLAR CANCER FOUNDATION, founded in 2009, is a community nonprofit in the Diseases & Disorders sector that reported $3.0M in total revenue in fiscal year 2023. Revenue fell 51% from the prior year — a significant decline worth monitoring. Expenses of $5.5M exceeded revenue, resulting in a 85% operating deficit.
FIBROLAMELLAR CANCER FOUNDATION,(THE "FOUNDATION") WAS ESTABLISHED TO RAISE AWARENESS AND RESEARCH FUNDS FOR FIBROLAMELLAR CARCINOMA, A RARE FORM OF LIVER CANCER THAT IS PRIMARILY SEEN IN TEENS AND YOUNG ADULTS. CURRENTLY, THERE ARE NO VIABLE TREATMENT OPTIONS OTHER THAN LIVER RESECTION SURGERY. OUR MISSION IS TO FIND A CURE AND RELIABLE TREATMENT OPTIONS FOR THOSE DIAGNOSED WITH THIS RARE DISEASE AS WELL AS ENHANCE COMMUNICATIONS AMONG HEALTHCARE PROFESSIONALS AND PATIENTS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $2,960,135 | $6,076,635 | -0.5% |
| Expenses | $5,485,040 | $2,563,688 | +1.1% |
| Net Income | $-2,524,905 | $3,512,947 | -1.7% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| MARNA O DAVIS | CO-CHAIRPERSON | 25.00 |
Officer
Director
|
$0 | $0 | $0 |
| CHARLES W BEERMANN | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| DEREK GILCHRIST | DIRECTOR, SECRETARY | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| ANNE ADLER | DIRECTOR | 25.00 |
Director
|
$0 | $0 | $0 |
| JOHN CRAIG | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| TAL FRIEDMAN | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| CHARLES A DAVIS | CO-CHAIRPERSON | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| LESLIE GRAVES | TREASURER | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| CRAIG MARTIN | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| KURT LOSERT | CEO | 40.00 |
Officer
Director
|
$273,188 | $6,793 | $279,981 |
| DAVID WERMUTH | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| GUY LEVY | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| DR MARK FURTH | SCIENTIFIC DIRECTOR | 40.00 |
Highest
|
$159,650 | $6,777 | $166,427 |
| JOHN HOPPER | DIRECTOR(RETIRED 05/23) | 1.00 |
|
$88,718 | $3,711 | $92,429 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $2,960,135 | $5,485,040 | $10,499,605 | $-2,524,905 |
| 2022 | $6,076,635 | $2,563,688 | $10,981,422 | $3,512,947 |
| 2021 | $4,041,093 | $1,865,036 | $7,664,472 | $2,176,057 |
| 2020 | $1,841,395 | $2,741,615 | $5,395,682 | $-900,220 |
| 2019 | $1,772,024 | $1,757,184 | $5,019,229 | $14,840 |
| 2018 | $1,712,900 | $1,073,035 | $4,969,117 | $639,865 |
Compare THE FIBROLAMELLAR CANCER FOUNDATION with other nonprofits in Connecticut and across the country.